Shandong state-owned antibiotics and API manufacturer, a longtime major Chinese producer of bulk antibiotic drugs.
Shandong state-owned antibiotics and API manufacturer, a longtime major Chinese producer of bulk antibiotic drugs.
Sells antibiotic active ingredients in bulk to formulators in China and abroad at prices close to commodity levels, while its finished antibiotic drugs go to hospitals through distributors. Tighter rules on antibiotic use and plant emissions shape its results.
In one line: A Chinese state-owned generic antibiotics maker.
Moat: none (scale). Legacy scale in commodity antibiotics without a differentiated product line.
Headquarters: Jining, Shandong, China · Employees: 6,469
Size Shandong Lukang Pharmaceutical (600789.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.05B, the 2080th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.74 on 18 Nov 2026.
Performance Over six months the shares fell 18.4%, against -8.7% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 6.5% over the last twelve months (peer median +3.1%); the operating margin is 2.8% (peer median 9.7%).
Valuation It trades at 1.5× enterprise value to sales against a peer median of 3.1× (4th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.4 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥5.74B | CN¥5.74B | CN¥6.18B | CN¥6.12B | CN¥5.60B |
| Revenue growth | — | -7% | +1% | +9% | — |
| Gross profit | CN¥1.48B | CN¥1.14B | CN¥1.34B | CN¥1.40B | CN¥1.15B |
| EBITDA | n/a | CN¥633M | CN¥695M | CN¥660M | CN¥541M |
| Net income | CN¥136M | CN¥112M | CN¥395M | CN¥246M | CN¥138M |
| Free cash flow | CN¥161M | CN¥359M | CN¥124M | CN¥266M | CN¥16.0M |
| Capital expenditure | CN¥366M | CN¥339M | CN¥279M | CN¥338M | CN¥428M |
| Total debt | CN¥2.82B | CN¥3.19B | CN¥3.44B | CN¥3.44B | CN¥3.36B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Shandong Lukang Pharmaceutical 600789.SS | $1.05B | -18% | -7% | 3% | 1.5× | 2.5% |
| North China Pharmaceutical 600812.SS | $1.08B | -12% | -21% | 5% | 2.4× | 1.0% |
| Northeast Pharmaceutical 000597.SZ | $895M | -14% | -6% | 3% | 0.9× | -7.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600789.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.7% | -4.7% | 7th lowest of 21 |
| 6-month return | -18.4% | -8.7% | 6th lowest of 21 |
| Distance from 52-week high | -38.1% | -31.7% | 7th lowest of 21 |
| Revenue growth (TTM) | -6.5% | +3.1% | 6th lowest of 18 |
| Operating margin | 2.8% | 9.7% | 5th lowest of 19 |
| EV / Sales | 1.5× | 3.1× | 4th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 2.5% | 1.0% | 7th most demanding of 14 |
| Growth delivered (Del g) | +6.5% | +7.7% | 7th lowest of 14 |
| Hurdle (Req g minus delivered) | -4.0 pp | -3.6 pp | 7th least demanding of 14 |
| ROIC minus cost of capital | +0.4 pp | -0.1 pp | 9th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | 1.5× | 2.5% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 8.1× | 40.8% | +13.8% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 3.2× | -5.6% | +12.7% |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 3.0× | n/a | n/a |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 1.7× | -6.5% | -7.7% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 1.2× | -0.3% | +12.1% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 4.2× | 4.4% | +7.7% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 4.0× | 7.5% | -4.5% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 2.3× | 4.3% | +3.5% |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 0.9× | -10.7% | -7.0% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 17.3× | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | 2.4× | 1.0% | -4.2% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 1.3× | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | 49.6× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | 19.3× | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 4.2× | -2.0% | +18.7% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 5.2× | 12.7% | +19.4% |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 1.5× | -3.6% | +4.2% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 2.3× | 4.9% | +11.3% |